RxDoctor Payments Data

Matthew Levy, DO

Cardiovascular Disease · Paoli, PANPI 1033442496

Payments from drug & device makers

$2,108in general payments, 2019–2025

Across 48 payments — averaging $43.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$853
  • Pfizer$219
  • Amgen$207
  • AstraZeneca$160
  • Amarin Pharma, Inc.$143
  • Johnson & Johnson$122
  • plus $403 from 8 others

What the payments were for

  • Travel & lodging$71734%
  • Food & beverage$1,37365%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,108 in reported general payments places this provider in the 50th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$779,507
Medicare patients
1,713
Services billed
5,640

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban392$496,156
XareltoRivaroxaban49$74,678
EntrestoSacubitril/Valsartan34$62,436
BrilintaTicagrelor46$39,235
Repatha SureclickEvolocumab37$38,479
JardianceEmpagliflozin23$22,480
Metoprolol Succinate491$8,342
VascepaIcosapent Ethyl23$7,270
Atorvastatin Calcium590$6,477
Ezetimibe144$5,493
Rosuvastatin Calcium287$5,244
Valsartan87$2,840
Amiodarone Hcl27$2,713
Ranolazine ErRanolazine16$2,696
Losartan Potassium161$2,226

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$219$496,156392 claims
Johnson & JohnsonXarelto$122$74,67849 claims
NovartisEntresto$55$62,43634 claims
AstraZenecaBrilinta$160$39,23546 claims
Boehringer IngelheimJardiance$58$22,48023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Paoli

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →